
HealthEquity (HQY) Stock Forecast & Price Target
HealthEquity (HQY) Analyst Ratings
Bulls say
HealthEquity is a leading provider of healthcare savings and spending solutions with a strong focus on personalized benefits and investment advice. The company's early innings are reflective of its potential for growth, with only 10,000 current HSA account holders in its marketplace and a potential $10 million in new revenue. The company's investment in automation and AI is expected to drive further gross margin expansion, and its leadership team's focus on digitizing the platform holds the potential for significant growth and margin expansion in the future. With a strong balance sheet and liquidity, HealthEquity is also positioned for inorganic growth opportunities in the fragmented HSA market. The regulatory landscape is also improving for potential TAM expansion, and the company is positioned to achieve its long-term targets of a $300 billion market with >30% revenue share. Management's focus on expanding the company's digital platform, increasing win rates, new marketplace revenue, TAM expansion and inorganic growth opportunities are all factors that contribute to a positive outlook for this stock. Additionally, the company's strong financials, with consistent account growth, improved margins, and a discounted trading level, support an Outperform rating and price target of $110.
Bears say
HealthEquity is facing a number of risks, such as declining interest rates, increasing competition, and potential changes in the regulatory environment. Additionally, there is growing popularity of alternative payment methods and a slow post-pandemic recovery which could impact the company's performance. HQY has a Nominating, Governance, and Corporate Sustainability Committee and encourages sustainability through its commuter benefits and volunteering programs. However, the company still faces risks related to cybersecurity attacks and potential fraud. While the company has shown strong results in terms of HSA growth and cost discipline, it is important to monitor the ongoing litigation and potential regulatory changes that could impact its business. Overall, these risks contribute to the negative outlook on HealthEquity's stock.
This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.
HealthEquity (HQY) Analyst Forecast & Price Prediction
Start investing in HealthEquity (HQY)
Order type
Buy in
Order amount
Est. shares
0 shares